Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: Systematic review and meta-analysis

British Journal of Psychiatry

Volumn 196, Issue 5, 2010, Pages 346-353

  Tsoi, Daniel Tai Yin ^a,b,c   Porwal, Mamta ^d   Webster, Angela Claire ^b,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; INSOMNIA; MENTAL HEALTH; META ANALYSIS; MUSCLE STIFFNESS; NERVOUSNESS; PREVALENCE; SCHIZOPHRENIA; SELF REPORT; SIDE EFFECT; SMOKING CESSATION; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TREATMENT DURATION; WAKEFULNESS; XEROSTOMIA;

ADULT; BUPROPION; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIC PSYCHOLOGY; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 77951734628     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.109.066019     Document Type: Conference Paper

References (57)

1. World Health Organization. Policy Recommendations on Smoking Cessation and Treatment of Tobacco Dependence. WHO, 2003.
2. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76: 135-157
3. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997; 42: 1-5. (Pubitemid 27293529)
4. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999; 156: 1751-1757 (Pubitemid 29517568)
5. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res 2005; 79: 323-335 (Pubitemid 41457273)
6. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993; 150: 1856-1861 (Pubitemid 23356580)
7. Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 2004; 18: 457-474 (Pubitemid 39665114)
8. Addington J, el-Guebaly N, Addington D, Hodgins D. Readiness to stop smoking in schizophrenia. Can J Psychiatry 1997; 42: 49-52.
9. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031.
10. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6: 159-166
11. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288: 88-92.
12. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 2003; 168: 347-358 (Pubitemid 36920920)
13. Strasser K. Smoking Reduction and Cessation for People with Schizophrenia: Guidelines for General Practitioners. SANE Australia & Department of Psychiatry, University of Melbourne, 2001.
14. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
16. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; 35: S93-100. (Pubitemid 29133030)
17. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303. (Pubitemid 40363436)
18. Fiore M, Jaén C, Baker T, Bailey W, Benowitz NL, Curry S, et al. Treating Tobacco Use and Dependence: 2008 Update - Clinical Practice Guideline. United States Department of Health and Human Services, 2008.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
20. Fatemi S, Stary J, Hatsukami D, Murphy S. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr Res 2005; 76: 353-356 (Pubitemid 40804782)
21. George TP, Hitsman B, Papandonatos GD, Sacco KA, Vessicchio JC, Dudas M, et al. Predictors of smoking cessation in schizophrenia: analysis of data from three sequential controlled clinical trials. Neuropsychopharmacol 2004; 29 (suppl 1): s103.
22. Evins A, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007; 27: 380-386 (Pubitemid 47075510)
23. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008; 63: 1092-1096
24. Evins AE, Cather C, Culhane M, Birnbaum AS, Horowitz J, Hsieh E, et al. A placebo-controlled study of bupropion SR added to high dose nicotine replacement therapy for smoking cessation or reduction in schizophrenia Nicotine Tob Res 2007; 9 (suppl 2): s101.
25. George TP, Vessicchio JC, Weinberger AH, Sacco KA. Sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia. Society for Research on Nicotine and Tobacco 13th Annual Meeting. Society for Research on Nicotine and Tobacco, 2007 (http://www.srnt.org/ meeting/2007/pdf/onsite/2007SRNTAbstracts-FINAL.pdf).
26. Sacco KA, Hitsman B, Papandonatos GD, Vessicchio JC, Dudas MM, Termine A, et al. Predictors of smoking cessation in schizophrenia: analysis of data from three sequential controlled clinical trials. Society for Research on Nicotine and Tobacco 10th Annual Meeting Society for Research on Nicotine and Tobacco, 2004 (http://63.84.94.99/srnt/abstract/2004/a/retrieveresponse.lasso).
27. George TP, Vessicchio J, Allen T, Weinberger A, Sacco KA. A randomized, double-blind, placebo-controlled trial of sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia: neuropsychological predictors of treatment outcome. Neuropsychopharmacol 2006; 31 (suppl 1): s254-5.
28. Evins A, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005; 25: 218-225 (Pubitemid 40685784)
29. Evins A, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 2005; 66: 1184-1190 (Pubitemid 41442287)
30. Evins AE, Cather C, Culhane M, Freudenreich O, Rigotti NA, Goff DC. Smoking cessation in schizophrenia: a double blind placebo controlled trial of bupropion SR added to cognitive behavioral therapy. Biological Psychiatry 2004; 55: 226S.
31. Evins AE, Cather C, Goff DC, Olm-Shipman C, Rigotti NA. A placebo controlled trial of bupropion SR for smoking cessation in schizophrenia. Society for Research on Nicotine and Tobacco 9th Annual Meeting. Society for Research on Nicotine and Tobacco, 2003 (http://63.84.94.99/srnt/abstract/r/ retrieveresponse.lasso?-MaxRecords=1&-SortField=Abstract-Title&- SortOrder=ascending&-Op=cn&Abstract-Title=&-Op=cn&Abstract= &-Op=cn&Authors=evins&-SkipRecords=0).
32. Evins A, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001; 3: 397-403. (Pubitemid 33101067)
33. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002; 52: 53-61. (Pubitemid 34655556)
34. Evins A, Cather C, Goff DC, Rigotti NA. Increased smoking cessation and reduction: two years following a smoking cessation trial in patients with schizophrenia. Society for Research on Nicotine and Tobacco 9th Annual Meeting. Society for Research on Nicotine and Tobacco, 2003 (http://63.84.94.99/srnt/ abstract/a/retrieveresponse.lasso).
35. Vessicchio JC, Termine A, Bregartner TA, George TP. Bupropion versus placebo for smoking cessation in schizophrenia. Drug Alcohol Depend 2002; 66: s187. (Pubitemid 34655556)
36. Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 2004; 65: 307-311
37. Weiner E, Buchanan R, Gold J, Ball P, Bennett M. A comparison of bupropion SR and placebo for smoking cessation in schizophrenia. Schizophr Res 2003; 60: 305-306
38. Weiner E, Ball MP, Buchanan R, Gold JM. A comparison of bupropion SR and placebo for smoking cessation. Schizophr Bull 2007; 33: 465.
39. Eliasson B, Hjalmarson A, Kruse E, Landfeldt B, Westin A. Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res 2001; 3: 249-255 (Pubitemid 32821652)
40. Hatsukami DK, Kotlyar M, Allen S, Jensen J, Li S, Le C, et al. Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest 2005; 128: 2528-2537 (Pubitemid 41507604)
41. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121 (Pubitemid 41773510)
42. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21-28 (Pubitemid 30623604)
43. Daumit GL, Goldberg RW, Anthony C, Dickerson F, Brown CH, Kreyenbuhl J, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis 2005; 193: 641-646 (Pubitemid 41475857)
44. Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003; 29: 393-397 (Pubitemid 37187700)
45. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. Br J Psychiatry 2003; 183: 534-539
46. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480-491
47. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.
48. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349
49. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217
50. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001; 58: 573-578 (Pubitemid 32523737)
51. Zwar N, Richmond R, Borland R, Peters M, Stilman S, Litt J, et al. Smoking cessation Pharmacotherapy: An Update for Health Professionals. Royal Australian College of General Practitioners, 2007.
52. Department of Health. Choosing Health: Making Healthier Choices Easier. Department of Health, 2004.
53. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007; 9: 821-833
54. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006; 31: 231-242
55. Shearer J, Shanahan M. Cost effectiveness analysis of smoking cessation interventions. Aust N Z J Public Health 2006; 30: 428-434
56. Cornuz J, Pinget C, Gilbert A, Paccaud F. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol 2003; 59: 201-206
57. Bertram MY, Lim SS, Wallace AL, Vos T. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Tob Control 2007; 16: 255-260